title: Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
abstract: The discovery of the tumor-inhibitory properties of asparaginase (ASNase) began in the early 1950s with the observation that guinea pig serum-treated lymphoma-bearing mice underwent rapid and often complete regression. About 4000 cases of acute lymphoblastic leukemia (ALL) are diagnosed very year in the US and many more through out the world. The majority of these cases are in children and young adults, making ALL the most common form of malignancy in these age groups. The treatment protocols of ALL are complex and use 6-12 drugs. Consequently, the improvement in the protocol design has improved significantly the success rate for long-term event-free survival in the past 20-30 years, which is now approximately 75% for patients afflicted with the higher risk ALL features and just above this percentage for patients with standard or good features. Despite this success, approximately 15% of patients die from ALL, making leukemic relapse the most common cause of treatment failure in pediatric oncology. ASNases have been the cornerstone of ALL therapies since the late 1970s. Native or pegylated L-asparaginase (ASNase or PEG-ASNase) are highly specific for the deamination of L-asparagine (Asn) to aspartic acid and ammonia. Depletion of Asn leads to a nutritional deprivation and inhibition of protein biosynthesis, resulting in apoptosis in T-lymphoblastic leukemias, which require Asn from external sources. The reactions of the host exposed to repeated ASNase treatments as well as the up-regulation of the mammalian enzymes to overcome the ASN-depletion toxic condition are of significant importance and may make us relearn the lessons on this important antileukemic drug.
authors: CHLA, Department of Pediatrics, Division of Hematology/Oncology, Keck School of Medicine, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA. vavramis@chla.usc.edu
authors: Vassilios I
authors: VI
authors: Avramis
authors: Prakash Nidhi
authors: PN
authors: Tiwari
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D001215:Asparaginase / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000737:chemistry*; D006801:Humans; D011092:Polyethylene Glycols / Q000737:chemistry*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D011092:Polyethylene Glycols; D001215:Asparaginase
references: Int Arch Allergy Appl Immunol. 1971;40(3):463-9
references: 4993767
references: Leuk Lymphoma. 1993;10 Suppl:147-50
references: 8481663
references: Leukemia. 2003 Nov;17(11):2254-6
references: 14523472
references: J Biol Chem. 1976 Sep 10;251(17):5375-80
references: 956189
references: Semin Oncol. 1982 Mar;9(1):5-13
references: 6461924
references: Arch Biochem Biophys. 1964 May;105:450-2
references: 14186753
references: Cancer. 1970 Feb;25(2):241-3
references: 4905151
references: J Natl Cancer Inst. 1965 Dec;35(6):967-74
references: 5856684
references: Cancer Res. 1966 Feb;26(2):208-11
references: 5903173
references: Proc Natl Acad Sci U S A. 1966 Nov;56(5):1516-9
references: 5339624
references: J Bacteriol. 1974 Feb;117(2):593-600
references: 4590479
references: Cancer Chemother Pharmacol. 2002 Aug;50(2):117-20
references: 12172975
references: J Exp Med. 1963 Jul;118:99-120
references: 14015821
references: Biochim Biophys Acta. 1975 Feb 24;383(1):30-9
references: 1173050
references: J Clin Oncol. 2005 Nov 1;23(31):7936-41
references: 16258093
references: J Exp Med. 1953 Dec;98(6):565-82
references: 13109110
references: Cancer Res. 1979 Oct;39(10):3893-6
references: 383278
references: Eur J Biochem. 1996 Oct 1;241(1):201-7
references: 8898907
references: J Bacteriol. 1976 Feb;125(2):719-27
references: 1107330
references: Lancet. 1968 Oct 5;2(7571):776-7
references: 4175572
references: N Engl J Med. 2004 Aug 12;351(7):657-67
references: 15306667
references: Proc Soc Exp Biol Med. 1965 Jun;119:325-7
references: 14328879
references: J Exp Med. 1966 Jan 1;123(1):55-74
references: 5902571
references: Blood. 2001 Mar 1;97(5):1211-8
references: 11222362
references: Blood. 2000 Sep 1;96(5):1709-15
references: 10961868
references: Clin Pharmacokinet. 2005;44(4):367-93
references: 15828851
references: Br J Haematol. 2005 Dec;131(5):579-87
references: 16351633
references: Drugs Aging. 2005;22(12):983-1012
references: 16363884
references: Cancer Res. 1967 Dec;27(12):2619-31
references: 5237354
references: Anticancer Res. 2004 Mar-Apr;24(2C):1121-5
references: 15154634
references: Med Pediatr Oncol. 2002 May;38(5):310-6
references: 11979454
references: Pediatr Blood Cancer. 2006 Aug;47(2):141-6
references: 16425271
references: Cancer Chemother Pharmacol. 1989;24(4):203-10
references: 2473850
references: J Clin Oncol. 1993 Sep;11(9):1780-6
references: 8355045
references: Clin Cancer Res. 2004 Aug 15;10(16):5335-41
references: 15328169
references: Mol Cancer Ther. 2005 Dec;4(12):2008-15
references: 16373716
references: Blood. 2002 Mar 15;99(6):1986-94
references: 11877270
references: Br J Haematol. 2001 Dec;115(4):983-90
references: 11843837
references: Indian J Cancer. 2005 Apr-Jun;42(2):65-9
references: 16141504
references: Cancer Treat Rep. 1981;65 Suppl 4:111-4
references: 7049374